Depreciation

EQS-News: H&R GmbH & Co. KGaA publishes Annual Report 2023

Retrieved on: 
星期三, 四月 10, 2024
EUR, Tax, Depreciation

H&R GmbH & Co. KGaA (H&R KGaA; ISIN DE000A2E4T77) achieved an operating result (EBITDA - consolidated earnings before income taxes, other financial income and expenses as well as depreciation, amortization, impairment and write-ups of intangible assets and property, plant and equipment) of EUR 92.7 million for financial year 2023 (2022: EUR 124.9 million); (for the other earnings levels, see the "Key figures for H&R KGaA" table below).

Key Points: 
  • H&R GmbH & Co. KGaA (H&R KGaA; ISIN DE000A2E4T77) achieved an operating result (EBITDA - consolidated earnings before income taxes, other financial income and expenses as well as depreciation, amortization, impairment and write-ups of intangible assets and property, plant and equipment) of EUR 92.7 million for financial year 2023 (2022: EUR 124.9 million); (for the other earnings levels, see the "Key figures for H&R KGaA" table below).
  • Below the line, consolidated net income attributable to shareholders amounted to EUR 10.6 million (2022: EUR 42.7 million).
  • This was EUR 223.7 million less than in the previous year (2022: EUR 1,576.0 million) due to price and volume factors.
  • Key figures for H&R KGaA:

EQS-News: STS Group AG publishes annual report 2023 - Forecast well met thanks to positive development in all regions

Retrieved on: 
星期三, 四月 10, 2024
Annual, Annual report, Tax, General Standard, Growth, Frankfurt Stock Exchange, SMC, STS Group, Plastic, Depreciation, Material

The results confirm that the STS Group AG has well met its annual forecast for sales revenue, EBITDA and EBITDA margin in the 2023 financial year.

Key Points: 
  • The results confirm that the STS Group AG has well met its annual forecast for sales revenue, EBITDA and EBITDA margin in the 2023 financial year.
  • Alberto Buniato, CEO of STS Group AG: "We are on the right track with the STS Group.
  • The strong growth of 18.2% is in line with the annual forecast and was driven by all three segments.
  • The Annual Report 2023 of STS Group AG will be available for download on April 11, 2024 at https://www.sts.group/investor-relations/publications .

EQS-News: Krones plans to pay dividend of €2.20 per share for successful 2023 financial year

Retrieved on: 
星期三, 四月 10, 2024
Annual, Tax, EBT, Science Based Targets initiative, Growth, Supervisory board, Carbon accounting, Policy, Acquisition, Science, ROCE, Annual report, Depreciation, Krones

The steeply rising demand for resource-efficient, low-emission machinery, systems and solutions will contribute significantly to the continuation of Krones’ profitable growth course.

Key Points: 
  • The steeply rising demand for resource-efficient, low-emission machinery, systems and solutions will contribute significantly to the continuation of Krones’ profitable growth course.
  • Alongside digitalisation and service quality, sustainability is a strategic focus for Krones and is the most important driver of innovation and growth.
  • Krones increased revenue by 12.2% in the financial year 2023 compared to 2022, from €4,209.3 million to €4,720.7 million.
  • The company thus exceeded the upgraded growth target of 11% to 13% published in July 2023 (previously: 8% to 11%).

EQS-News: IKB Deutsche Industriebank AG figures for the 2023 financial year: Solid figures achieved in a difficult environment

Retrieved on: 
星期三, 四月 10, 2024
ESF, Tax, IKB, Pressure, Risk management, Growth, Environment, Risk, Pension, IKB Deutsche Industriebank, Bank, Sale, Acquisition, Common equity, Depreciation, Administration, NPL, EDB, KfW, Corporation

IKB Deutsche Industriebank AG figures for the 2023 financial year: Solid figures achieved in a difficult environment

Key Points: 
  • IKB Deutsche Industriebank AG figures for the 2023 financial year: Solid figures achieved in a difficult environment
    The issuer is solely responsible for the content of this announcement.
  • IKB Deutsche Industriebank AG figures for the 2023 financial year: Solid figures achieved in a difficult environment
    Ample liquidity with free available liquidity reserve of €1.4 billion (previous year: €1.2 billion)
    Dr Michael Wiedmann, Chairman of the Board of Managing Directors of IKB: “We have met our annual targets and are on track to achieving our medium-term goals.
  • 2023 was largely characterised by the increase in market interest rates against a difficult economic backdrop.
  • Table: IKB income statement for the 2023 financial year (Group, in accordance with German commercial law)

Prodware: Strong increase in Current Operating Income: €49.1 million (+68%) - Net Profit impacted by exceptional items

Retrieved on: 
星期三, 四月 10, 2024
NUT, One stop shop, Growth, Depreciation, Beauty salon

With the product mix of recent acquisitions leaning towards more trading, EBITDA margin reached 18.7% in 2023.

Key Points: 
  • With the product mix of recent acquisitions leaning towards more trading, EBITDA margin reached 18.7% in 2023.
  • With reduced depreciation and provision expenses (€20.3 million in 2023 compared to €21.5 million in 2022), Current Operating Income saw a stronger increase to €49.1 million, resulting in a robust operating margin of 12.9%.
  • Financial Result stands at - €19.9 million in 2023, down by - €8.8 million from 2022.
  • This decrease is due to higher interest rates and an increase in debt resulting from acquisitions made during the year.

EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

Retrieved on: 
星期三, 四月 10, 2024
Malignancy, Spanish mythology, State university system, Patient, Sale, Renal cell carcinoma, Clinical trial, Neoplasm, Therapy, Depreciation, HPHA, USD, Marketing, GLP, Health, Research, ATACS, EPO, Immune system, ADC, BLA, ATAC, Food, Biologics license application, Disease, Magenta, Multiple myeloma, AACR, GCC, Annual report, FDA, Diagnosis, EUR, Supervisory board, Accounting, PET, EDT, Spacecraft, Amanitin, European Patent Convention, Patent, Eli Lilly and Company, Binghamton University, Pharmaceutical industry

Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).

Key Points: 
  • Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).
  • As a result, Heidelberg Pharma lost sales revenue in the low single-digit millions for the 2023 financial year.
  • In April 2023, Heidelberg Pharma signed a termination agreement with Magenta under which all licensed ATAC rights and some Magenta patents were assumed by Heidelberg Pharma.
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.

EQS-News: Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges

Retrieved on: 
星期三, 四月 10, 2024
Annual, Tax, Aggression, COVID-19, Euromed, Supervision, Acquisition, Management, Annual report, Depreciation, PPA, Parallel, Lithium

Grünwald, 28 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2023.

Key Points: 
  • Grünwald, 28 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2023.
  • Despite a difficult macroeconomic environment, Dermapharm succeeded in maintaining its growth trajectory and hitting the upper end of the guidance range in 2023.
  • "In addition to the end of the boom phase associated with vaccine production, 2023 was also shaped by various other macroeconomic and geopolitical challenges.
  • The Annual General Meeting of Dermapharm Holding SE will take place on 27 June 2024.

EQS-News: RHÖN-KLINIKUM AG looks back on successful financial year 2023

Retrieved on: 
星期三, 四月 10, 2024
Asclepius, Tax, University, Environment, Partnership, COVID-19, Patient, Hospital, Depreciation, Legislation, Person, Renewable energy

RHÖN-KLINIKUM AG has met its financial targets as per forecast.

Key Points: 
  • RHÖN-KLINIKUM AG has met its financial targets as per forecast.
  • Earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at 105.9 million euros (previous year: 105.6 million euros).
  • “In the past year as well, RHÖN-KLINIKUM AG demonstrated its financial efficiency and put in a solid performance.
  • RHÖN-KLINIKUM AG is looking to achieve CO2-greenhouse gas neutrality in Scope 1 and Scope 2 emissions by financial year 2040.

EQS-News: SURTECO GROUP SE: Preliminary result for the business year 2023

Retrieved on: 
星期三, 四月 10, 2024
Baseboard, Acquisition, Annual report, Plastic, Depreciation, Income tax, PPA

EBITDA at € 66.6 million, adjusted EBITDA at € 86.4 million

Key Points: 
  • EBITDA at € 66.6 million, adjusted EBITDA at € 86.4 million
    Buttenwiesen, 25 March 2024 – SURTECO GROUP SE has generated Group sales amounting to € 835.1 million according to unaudited preliminary figures presented.
  • Provisional earnings before financial result, income tax and depreciation and amortization (EBITDA) amount to € 66.6 million (2022: € 84.2 million).
  • SURTECO GROUP SE with registered office in Buttenwiesen is a mid-sized enterprise listed on the stock exchange with international operations.
  • Customers of the SURTECO Group primarily come from wood-based, flooring and furniture industries, as well as from interior design.

EQS-News: HHLA continues future-oriented investments despite challenging conditions

Retrieved on: 
星期三, 四月 10, 2024
Annual, Real estate, Growth, Supervisory board, Port of Hamburg, TK, Speicherstadt, TEU, Policy, Transport, Container, Investment, Intermodal transport, Depreciation, Port, HHLA, Intermodal freight transport

CEO Angela Titzrath: “In a challenging market environment, HHLA is continuing to pursue its forward-looking investments to modernise its terminals and expand its European network.”

Key Points: 
  • CEO Angela Titzrath: “In a challenging market environment, HHLA is continuing to pursue its forward-looking investments to modernise its terminals and expand its European network.”
    Hamburger Hafen und Logistik AG (HHLA) recorded a drop in revenue and earnings in the 2023 financial year.
  • Angela Titzrath, HHLA’s Chief Executive Officer: “In light of the extremely difficult conditions for global trade, HHLA has performed well in 2023, particularly in comparison to its major competitors.
  • The notable increase in throughput volumes at the multi-function terminal HHLA PLT Italy was unable to offset this shortfall.
  • HHLA therefore continues to pursue its dividend policy of distributing between 50 and 70 percent, where possible, of the Port Logistics subgroup’s relevant net profit for the year to its shareholders.